Medical Device Player Beyond Air's Subsidiary Reveals Encouraging Data From Early-Stage Cancer Study

Beyond Cancer Ltd, an affiliate of Beyond Air Inc XAIR, announced that the Phase 1 Study evaluating ultra-high concentration nitric oxide (UNO) in advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors has cleared the first cohort of 25,000 ppm single dose by the Safety Review Committee with no reported dose-limiting toxicities.

The first-in-human, open-label, non-randomized Phase 1 study is being conducted in two parts: Dose Escalation and Dose Expansion. The Dose Escalation consists of three UNO cohorts (25,000, 50,000, and 100,000 ppm) of three to six patients. 

The Dose Expansion will begin once the recommended dose is determined in the Dose Escalation portion. 

The trial's primary objective is to assess the safety and tolerability of UNO, with a secondary objective of assessment of efficacy by immune biomarker response to UNO therapy.

Price Action: XAIR shares are up 1.17% at $2.15 on the last check Wednesday.